Active Biotech AB

Development of pharmaceuticals

Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in pivotal Phase 3 development for the treatment of relapsing remitting multiple sclerosis. Also, laquinimod is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington’s disease. Furthermore, commercial activities are conducted for the tasquinimod, SILC, ANYARA and paquinimod projects. Please visit www.activebiotech.com for more information.
CEO
Tomas Leanderson
"To develop innovative and effective pharmaceuticals within neurodegenerative diseases and cancer where major medical need exists"
  • Category
    Biotech
  • Founded
    1997
  • Public company
    Yes
  • Revenue
    16.3 MSEK in Sweden
  • Number of employees
    17
  • Chairman
    Mats Arnhög
  • Principal owners
    MGA Holding AB, Nordstjernan AB, Investor
Patents, projects and products